Entering text into the input field will update the search result below

RVL Pharma posts preliminary 42% sales growth for eye treatment

Jul. 07, 2022 9:02 AM ETRVL Pharmaceuticals plc (RVLPQ)By: Dulan Lokuwithana, SA News Editor1 Comment

White rising bar chart on blue background with copy space. Business economic and money investment concept. Goal and success theme. 3D illustration rendering graphic design.

Shutter2U/iStock via Getty Images

  • Citing preliminary financials, New Jersey-based RVL Pharmaceuticals (NASDAQ:RVLP) announced on Thursday that the company generated nearly $8.4M net product sales for its eye disease therapy Upneeq in 2Q 2022, implying a sequential growth of ~42%.

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Free money in plain sight. Why this company is worth only 132m when it might be driving 100m annual revenue on this high margin drug next year is beyond me.


SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RVL Pharmaceuticals plc
Baudax Bio, Inc.
NovaBay Pharmaceuticals, Inc.
cbdMD, Inc.
Sonoma Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.